<H1>Chapter DOI: 10.1007/978-1-60327-829-4_21<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>32</td></tr><tr><td>Springer references</td><td>4</td></tr><tr><td>Non Springer references</td><td>28</td></tr><tr><td>BibStructured Count</td><td width="10%">32</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>27</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_21</td><td>BibArticle</td><td>van Moorselaar RJ, Voest EE. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol 2002;197:239&#8211;50.</td><td><a href=http://dx.doi.org/10.1016/S0303-7207(02)00262-9>10.1016/S0303-7207(02)00262-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_21</td><td>BibArticle</td><td>Longoria RL, Cox MC, Figg WD. Antiangiogenesis: a possible treatment option for prostate cancer? Clin Genitourin Cancer 2005;4:197&#8211;202.</td><td><a href=http://dx.doi.org/10.3816/CGC.2005.n.033>10.3816/CGC.2005.n.033</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_21</td><td>BibArticle</td><td>Aragon-Ching JB, Dahut WL. The role of angiogenesis inhibitors in prostate cancer. Cancer J 2008;14:20&#8211;5.</td><td><a href=http://dx.doi.org/10.1097/PPO.0b013e318161c014>10.1097/PPO.0b013e318161c014</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_21</td><td>BibArticle</td><td>Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008;54:1089&#8211;94.</td><td><a href=http://dx.doi.org/10.1016/j.eururo.2008.01.082>10.1016/j.eururo.2008.01.082</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_21</td><td>BibArticle</td><td>Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888&#8211;93.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6_21</td><td>BibArticle</td><td>Figg WD, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001;28:62&#8211;6.</td><td><a href=http://dx.doi.org/10.1016/S0093-7754(01)90157-5>10.1016/S0093-7754(01)90157-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_21</td><td>BibArticle</td><td>Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532&#8211;9.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.05.074>10.1200/JCO.2004.05.074</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_21</td><td>BibArticle</td><td>Aragon-Ching JB, Li H, Gardner ER, Figg WD. Thalidomide analogues as anticancer drugs. Recent Patents Anticancer Drug Discov 2007;2:167&#8211;74.</td><td><a href=http://dx.doi.org/10.2174/157489207780832478>10.2174/157489207780832478</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_21</td><td>BibArticle</td><td>Shah SR, Tran TM. Lenalidomide in myelodysplastic syndrome and multiple myeloma. Drugs 2007;67:1869&#8211;81.</td><td><a href=http://dx.doi.org/10.2165/00003495-200767130-00005>10.2165/00003495-200767130-00005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_21</td><td>BibArticle</td><td>Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835&#8211;44.</td><td><a href=http://dx.doi.org/10.1038/nrd2130>10.1038/nrd2130</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_21</td><td>BibArticle</td><td>Steinbild S, Mross K, Frost A, et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007;97:1480&#8211;5.</td><td><a href=http://dx.doi.org/10.1038/sj.bjc.6604064>10.1038/sj.bjc.6604064</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_21</td><td>BibArticle</td><td>Chi KN, Ellard SL, Hotte SJ, et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008;19:746&#8211;51.</td><td><a href=http://dx.doi.org/10.1093/annonc/mdm554>10.1093/annonc/mdm554</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_21</td><td>BibArticle</td><td>Dahut WL, Scripture C, Posadas E, et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008;14:209&#8211;14.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-1355>10.1158/1078-0432.CCR-07-1355</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_21</td><td>BibArticle</td><td>Ryan CJ, Stadler WM, Roth B, et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 2007;25:445&#8211;51.</td><td><a href=http://dx.doi.org/10.1007/s10637-007-9050-y>10.1007/s10637-007-9050-y</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_21</td><td>BibArticle</td><td>Balasubramanian SP, Brown NJ, Reed MW. Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer 2002;87:1057&#8211;65.</td><td><a href=http://dx.doi.org/10.1038/sj.bjc.6600625>10.1038/sj.bjc.6600625</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_21</td><td>BibArticle</td><td>Jacobs EJ, Hsing AW, Bain EB, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev 2008;17:972&#8211;7.</td><td><a href=http://dx.doi.org/10.1158/1055-9965.EPI-07-2787>10.1158/1055-9965.EPI-07-2787</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_21</td><td>BibArticle</td><td>Sfar S, Saad H, Mosbah F, Chouchane L. Combined effects of the angiogenic genes polymorphisms on prostate cancer susceptibility and aggressiveness. Mol Biol Rep 2009;36(1):37&#8211;45.</td><td><a href=http://dx.doi.org/10.1007/s11033-007-9149-4>10.1007/s11033-007-9149-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_21</td><td>BibArticle</td><td>Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 2006;35:21&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/j.cyto.2006.07.003>10.1016/j.cyto.2006.07.003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_21</td><td>BibArticle</td><td>Onen IH, Konac E, Eroglu M, Guneri C, Biri H, Ekmekci A. No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population. Mol Biol Rep 2008;35:17&#8211;22.</td><td><a href=http://dx.doi.org/10.1007/s11033-006-9046-2>10.1007/s11033-006-9046-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_21</td><td>BibArticle</td><td>McCarron SL, Edwards S, Evans PR, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002;62:3369&#8211;72.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21_21</td><td>BibArticle</td><td>Langsenlehner T, Langsenlehner U, Renner W, et al. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur J Cancer 2008;44:1572&#8211;6.</td><td><a href=http://dx.doi.org/10.1016/j.ejca.2008.04.021>10.1016/j.ejca.2008.04.021</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_21</td><td>BibArticle</td><td>Iughetti P, Suzuki O, Godoi PH, et al. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 2001;61:7375&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR23_21</td><td>BibArticle</td><td>Li HC, Cai QY, Shinohara ET, et al. Endostatin polymorphism 4349G/A(D104N) is not associated with aggressiveness of disease in prostate cancer. Dis Markers 2005;21:37&#8211;41.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24_21</td><td>BibArticle</td><td>Fu XS, Choi E, Bubley GJ, Balk SP. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 2005;63:215&#8211;21.</td><td><a href=http://dx.doi.org/10.1002/pros.20190>10.1002/pros.20190</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_21</td><td>BibArticle</td><td>Li H, Bubley GJ, Balk SP, et al. Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate 2007;67:1354&#8211;61.</td><td><a href=http://dx.doi.org/10.1002/pros.20589>10.1002/pros.20589</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_21</td><td>BibArticle</td><td>Sitaras NM, Sariban E, Bravo M, Pantazis P, Antoniades HN. Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res 1988;48:1930&#8211;5.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR27_21</td><td>BibArticle</td><td>Timke C, Zieher H, Roth A, et al. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 2008;14:2210&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-1893>10.1158/1078-0432.CCR-07-1893</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_21</td><td>BibArticle</td><td>Dolloff NG, Russell MR, Loizos N, Fatatis A. Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor. Cancer Res 2007;67:555&#8211;62.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-2593>10.1158/0008-5472.CAN-06-2593</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_21</td><td>BibArticle</td><td>Kim SJ, Uehara H, Yazici S, et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 2006;98: 783&#8211;93.</td><td><a href=http://dx.doi.org/10.1093/jnci/djj211>10.1093/jnci/djj211</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_21</td><td>BibArticle</td><td>Hofer MD, Fecko A, Shen R, et al. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 2004;6:503&#8211;12.</td><td><a href=http://dx.doi.org/10.1593/neo.04157>10.1593/neo.04157</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_21</td><td>BibArticle</td><td>Albayrak S, Canguven O, Goktas C, Aydemir H, Koksal V. Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population. Urol Int 2007;79:312&#8211;5.</td><td><a href=http://dx.doi.org/10.1159/000109715>10.1159/000109715</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_21</td><td>BibArticle</td><td>Danforth KN, Rodriguez C, Hayes RB, et al. TNF polymorphisms and prostate cancer risk. Prostate 2008;68:400&#8211;7.</td><td><a href=http://dx.doi.org/10.1002/pros.20694>10.1002/pros.20694</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>